Dissacharide Patents (Class 514/53)
-
Patent number: 8975242Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.Type: GrantFiled: January 21, 2011Date of Patent: March 10, 2015Assignee: Wyeth LLCInventors: Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
-
Publication number: 20150065450Abstract: The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (HA), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the CD44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug.Type: ApplicationFiled: August 26, 2014Publication date: March 5, 2015Inventor: Hua-Yang Lin
-
Patent number: 8962593Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.Type: GrantFiled: July 17, 2014Date of Patent: February 24, 2015Assignee: Immune Design Corp.Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen
-
Patent number: 8957047Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.Type: GrantFiled: April 18, 2014Date of Patent: February 17, 2015Assignee: Immune Design Corp.Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen
-
Patent number: 8956638Abstract: A method is provided for the preparation of a poly(amic acid) in which ring opening polymerization is employed to react the monomers ethylenediaminetetraacetic dianhydride and paraphenylenediamine in an aprotic solvent. The resulting poly(amic acid) composition is suitable as a biocompatible material, such as a biomedical implant, implant coating material, tissue scaffold material, controlled release drug delivery vehicle, and cellular growth substrate.Type: GrantFiled: April 8, 2011Date of Patent: February 17, 2015Assignee: Axcelon Biopolymers CorporationInventors: Wankei Wan, Donna Padavan
-
Publication number: 20150045320Abstract: A flowable or spoonable medicament, food, food ingredient or food supplement is useful for inducing satiety. It comprises (a) one or more mono-, di- and/or oligosaccharides and (b) a methylcellulose, wherein the methylcellulose has anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is from 0.17 to 0.36, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups.Type: ApplicationFiled: October 11, 2012Publication date: February 12, 2015Applicant: DOW GLOBAL TECHNOLOGIES LLCInventors: Roland Adden, Matthias Knarr, Britta Huebner-Keese, Robert L. Sammler
-
Patent number: 8951989Abstract: A hydrogel tissue adhesive having decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide with a water-dispersible, multi-arm polyether amine in the presence of an oligomer additive, which promotes the degradation of the hydrogel. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery.Type: GrantFiled: April 9, 2010Date of Patent: February 10, 2015Assignee: Actamax Surgical Materials, LLCInventor: Mark E. Wagman
-
Publication number: 20150038454Abstract: Compositions comprising an antimicrobial effective concentration of sucralose and methods of using for treating pharyngeal and other bacterial conditions.Type: ApplicationFiled: July 31, 2014Publication date: February 5, 2015Inventor: Mary Malast
-
Publication number: 20150038455Abstract: The present disclosure provides for methods and compositions comprising a series of synthetic glycopolymers. The disclosure also relates to a kit which is suitable for carrying out the inventive methods.Type: ApplicationFiled: August 1, 2014Publication date: February 5, 2015Inventors: Gloria J. Sheng, Linda C. Hsieh-Wilson
-
Publication number: 20150038456Abstract: The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Inventors: Cecile Gousse, Pierre F. Lebreton, Nicolas Prost
-
Patent number: 8946194Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.Type: GrantFiled: October 7, 2011Date of Patent: February 3, 2015Assignee: Board of Regents, University of Texas SystemInventors: Sarah Mayes, Christine E. Schmidt
-
Patent number: 8940325Abstract: The present invention relates to the use of at least one compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and to the salts and complexes thereof as cleaning agents for a wound. The invention can be used in particular for preparing bandages intended for cleaning wounds.Type: GrantFiled: February 16, 2011Date of Patent: January 27, 2015Assignee: Laboratories UrgoInventors: Laurent Apert, Christelle Laurensou, Dominque Nicot
-
Publication number: 20150025035Abstract: The invented inositol and trehalose derivatives, prepared by introducing multiple units of the guanidine group to the backbone molecules, show excellent blood-brain barrier permeability, and accordingly, it can be easily transported to the brain tissues and utilized for the treatment of neurodegenerative diseases such as Alzheimer's disease and Huntington's disease.Type: ApplicationFiled: October 8, 2014Publication date: January 22, 2015Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Sung-Kee CHUNG, Woo Sirl LEE, Boram KIM, Jungkyun IM, Subhash C. GHOSH
-
Publication number: 20150025034Abstract: The aim of the invention is to propose a composition for the care and hygiene of the auditory canal, in particular a cerumenolytic composition, which is effective for dissolving and preventing the appearance of plugs of cerumen, which is free from products irritating to the auditory canal or a source of allergy, such as preservatives or surfactants of animal origin, which is biodegradable and non-toxic for the environment, which can be used under non-sterile conditions while ensuring satisfactory preservation and stability and which does not require rinsing after use thereof. To this end, the invention concerns a composition for the care and hygiene of the auditory canal that is characterised in that it comprises a pair of surfactants consisting of an N-acyl sarcosinate sodium salt having an HLB greater than or equal to 25 and a sucrose fatty acid ester having an HLB greater than or equal to 11.Type: ApplicationFiled: March 7, 2013Publication date: January 22, 2015Inventor: Laurent Batteur
-
Publication number: 20150025028Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.Type: ApplicationFiled: July 15, 2014Publication date: January 22, 2015Inventors: Guey-Jen LEE-CHEN, Hsiu-Mei HSIEH, Guan-Chiun LEE
-
Publication number: 20150018302Abstract: The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided.Type: ApplicationFiled: February 4, 2013Publication date: January 15, 2015Inventors: Ru Chih Huang, David Mold, Christopher Ruland, Yu-Chuan Liang, Jong Ho Chun
-
Patent number: 8933055Abstract: The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. These formulations have a high cidal activity in a short amount of time and provide stable copious foam. The formulations of the present invention also exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.Type: GrantFiled: September 21, 2011Date of Patent: January 13, 2015Assignee: Ecolab USA Inc.Inventors: Daniel E. Pedersen, Angela R. Eder, Charles A. Hodge
-
Publication number: 20150010627Abstract: The present invention relates to new pharmaceutical compositions of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to new pharmaceutical compositions for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis.Type: ApplicationFiled: January 29, 2013Publication date: January 8, 2015Inventors: Umit Cifter, Ali Turkyilmaz, Onur Mutlu, Gaye Ramazanoglu
-
Patent number: 8927504Abstract: The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener having a GLP-1 secretion-stimulating action, as well as use thereof for the manufacture of a medicament. The present invention also provides a method for treating or preventing obesity, comprising administering an effective amount of (a) a dipeptidyl peptidase 4 inhibitor and (b) a sweetener having a GLP-1 secretion-stimulating action to a patient suffering from symptoms of obesity.Type: GrantFiled: April 3, 2008Date of Patent: January 6, 2015Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Masaharu Shiotani, Tomomi Ishihara, Chiaki Matsushita
-
Publication number: 20150004147Abstract: The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to an individual a lactose composition with decreased lactose content in combination with effective amounts of prebiotics and/or probiotics.Type: ApplicationFiled: February 3, 2014Publication date: January 1, 2015Inventor: Andrew J. Ritter
-
Publication number: 20140348774Abstract: The present inventions relate to a number of fields including wound healing, a waterless antibacterial disinfectant, a surgical scrub, insect repellant, and methods of treating traumatic injuries, particularly those on the battlefield where there is a need to stabilize the patient and prevent infection.Type: ApplicationFiled: June 9, 2014Publication date: November 27, 2014Applicant: Aurora Pharmaceutical, LLCInventors: Michael Strobel, Gene Komer
-
Patent number: 8895612Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.Type: GrantFiled: December 9, 2013Date of Patent: November 25, 2014Assignee: Luitpold Pharmaceuticals, Inc.Inventors: Mary Jane Helenek, Marc L. Tokars, Richard P. Lawrence
-
Patent number: 8895557Abstract: Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.Type: GrantFiled: October 28, 2005Date of Patent: November 25, 2014Assignee: Pharma Mar, S.A., Sociedad UnipersonalInventors: Jacob Hendrik Beijnen, Bastiaan Nuijen, Pilar Calvo Salve, Maria Tobio Barreira
-
Patent number: 8895516Abstract: Saccharide-protein conjugates having a new type of linker are described. The conjugates comprising the new linker are prepared from modified saccharides comprising a moiety of the formula (I): -A-N(R1)-L-M wherein: A is a bond, —C(O)— or —OC(O)—; R1 is selected from H or C1-C6 alkyl; L is a C1-C12 alkylene group; and M is a masked aldehyde group. The new linker is especially useful for preparing conjugates of Neisseria meningitidis serogroup A saccharide. Conjugates having this new linker have improved immunogenicity compared to other types of conjugates.Type: GrantFiled: September 1, 2003Date of Patent: November 25, 2014Assignee: Novartis AGInventors: Aldo Giannozzi, Giovanni Averani, Francesco Norelli, Paolo Costantino
-
Publication number: 20140343010Abstract: The present invention provides novel co-crystal forms of dapagliflozin, namely a dapagliflozin lactose co-crystal and a dapagliflozin asparagine co-crystal, to pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating type 2 diabetes.Type: ApplicationFiled: May 23, 2014Publication date: November 20, 2014Applicant: MAPI PHARMA LTD.Inventors: Ehud MAROM, Shai RUBNOV
-
Patent number: 8889651Abstract: The invention relates to trehalose derivatives with general formula (I), a preparation method and uses thereof, wherein 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has anti-colon cancer 26-L5 cell invasion activity which is better than that of a natural product Brartemicin, IC50 is 0.10 ?g/mL (0.15 ?M), and when the IC50 is 10 ?g/mL, 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has no cytotoxicity, shows high-selectivity anti-tumor invasion activity and can be used for preparing medicaments for preventing and treating invasion and metastasis of colon cancer and the like.Type: GrantFiled: December 30, 2010Date of Patent: November 18, 2014Assignee: Joyochem Co., Ltd.Inventors: Zhaopeng Liu, Yongli Jiang
-
Publication number: 20140336144Abstract: Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor.Type: ApplicationFiled: May 19, 2014Publication date: November 13, 2014Inventors: Yuichi TEI, Nobuo SASAKI, Shigeki SUZUKI
-
Publication number: 20140335153Abstract: A method of preparing a thin film, the method comprising: (a) mixing a lipid, emulsifier, and solvent to provide a uniform first mixture; (b) contacting an active ingredient with the uniform first mixture to provide a thickened second mixture; (c) contacting a binder with the thickened second mixture to provide a slurry; and (d) hot extruding, casting, and condensing the slurry to provide the thin film; or cooling, shearing, mixing, casting, and condensing the slurry to provide the thin film.Type: ApplicationFiled: October 31, 2013Publication date: November 13, 2014Applicant: CURE Pharmaceutical CorporationInventors: Eric Allen, Robert Steven Davidson, Jose Bernardo
-
Publication number: 20140336146Abstract: The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (I).Type: ApplicationFiled: January 24, 2013Publication date: November 13, 2014Applicant: GALECTO BIOTECH ABInventors: Ulf Nilsson, Hakon Leffler, Balaram Mukhopadhyay, Vishal Rajput
-
Publication number: 20140336145Abstract: The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of oculopharyngeal muscular dystrophy (OPMD).Type: ApplicationFiled: June 30, 2014Publication date: November 13, 2014Inventor: Dalia MEGIDDO
-
Patent number: 8884004Abstract: The present invention provides a method for preparing colorless sucralose, wherein 4,1?,6?-trichloro-4,1?,6?-trideoxy-galactosucrose-6-acetate containing colored impurities formed during chlorination of sucrose-6-acetate is treated with sodium hypochlorite, where sodium hypochlorite acts both as a decolorizing agent and as a reagent for the ester hydrolysis.Type: GrantFiled: November 8, 2011Date of Patent: November 11, 2014Assignee: Divi's Laboratories, Ltd.Inventors: Murali Krishna Prasad Divi, Gundu Rao Padakandla, Mysore Aswatha Narayana Rao, Shaik Nowshuddin
-
Patent number: 8883715Abstract: A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AaXxYy wherein: A represents a monomer selected from the group consisting of a sugar or —(O—CH2—CH2—CO)—, X represents a carboxyl group bonded to monomer A, Y represents a sulfate or sulfonate group bonded to monomer A a represents the number of monomers A such that the mass of the polymers of formula (I) is greater than approximately 5,000 da, x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.Type: GrantFiled: April 12, 2013Date of Patent: November 11, 2014Inventors: Denis Barritault, Jean-Pierre Caruelle
-
Publication number: 20140328904Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen
-
Patent number: 8877735Abstract: Purified alkoxylated sucrose esters of the formula: wherein R is independently selected from: COR?; (CH2CH2O)xH; and (CH2CH2O)x COR?; wherein R? is a fatty acid compound having from about 2 to about 28 carbon atoms; and wherein x is a number selected from about 1 to about 50; wherein at least one of the R groups is an ester group that is directly esterified to the sucrose backbone; and wherein the alkoxylated sucrose ester composition further comprises: less than 1% aldehydes; less than 1% ketones; less than 1% benzyl halide; less that 1% mono-benzyl ether; less than 1% acetals; and less than 1% ketals.Type: GrantFiled: June 20, 2005Date of Patent: November 4, 2014Assignee: The Procter & Gamble CompanyInventor: Jared John Schaefer
-
Publication number: 20140323429Abstract: A method of manufacturing a medical drug of alleviating damage of gastrointestinal mucosal induced by a non-steroidal anti-inflammatory drug, NSAID, the medical drug being able to induce anti-inflammatory effect of the NSAID and being able to alleviate damage induced by the NSAID includes dissolving trehalose and the NSAID into one or more solutions, so as to obtain an approximately homogenously-mixed liquid mixture of the trehalose and the NSAID; in which the liquid mixture contains an intermolecular compound with the trehalose and the NSAID; and drying the liquid mixture so as to obtain the medical drug.Type: ApplicationFiled: June 3, 2014Publication date: October 30, 2014Applicant: NEXT21 K.K.Inventors: Yuichi Tei, Nobuo Sasaki, Shigeki Suzuki
-
Patent number: 8871744Abstract: The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor.Type: GrantFiled: July 18, 2011Date of Patent: October 28, 2014Assignee: B & G Partyers, LLCInventor: Donald L. Barbeau
-
Patent number: 8871739Abstract: Provided are methods for the solubilization of cellulose into soluble sugars without the need for high temperatures, high pressures, strong acid solutions, and/or added water. The produced sugars can be fermented into ethanol. In one embodiment, the method comprises contacting a cellulose-containing material with a solid acid material and agitating the cellulose-containing material and the solid acid material for a time sufficient to produce an aqueous solution comprising a quantity of soluble sugars.Type: GrantFiled: November 19, 2009Date of Patent: October 28, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventors: Richard G. Blair, Sandra M. Hick, Joshua H. Truitt
-
Publication number: 20140314834Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.Type: ApplicationFiled: April 18, 2014Publication date: October 23, 2014Applicant: IMMUNE DESIGN CORP.Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen
-
Publication number: 20140303114Abstract: This invention relates to the extraction and use of bioactive compounds from avocado seeds (var. Hass; Persea americana Mill) at room temperature. The extraction was performed with dichloromethane as a solvent using a simple diffusion mechanism within pressed avocado seeds. The extracted compounds were identified as furan derivative structures and fragments derived thereof that exhibited repellent and miticide activity against mite species of economic interest: Tetranychus urticae, Tetranychus cinnabarinus, Oligonychus yothersi, Panonychus citri, and Brevipalpus chilensis. The compounds obtained have the general structure of a disubstituted furan, as illustrated in FIG. 1, and the fragments thereof are derived from mono-substituted furans and from side-chain fragments. The utility of these compounds as repellents was determined over a 48-hour period, and their function as miticides was evaluated for 24 hours after application.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventor: Robinson Vargas Mesina
-
Publication number: 20140303115Abstract: A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Leo Pavliv, Brian Voss
-
Publication number: 20140299136Abstract: A method of modifying the content of certain bacteria in uncured tobacco material is provided, the method including contacting an uncured tobacco material with a treatment solution, wherein the treatment solution is selected from the group consisting of: (i) a solution comprising salt, sugar, or a combination thereof; (ii) a solution comprising one or more enzymes; and (iii) a solution comprising one or more probiotics, wherein said contacting provides a treated tobacco material having a reduced total bacterial content following harvest. In certain embodiments, the treated tobacco material is subsequently cured, and can optionally be fermented. Smoking articles and smokeless tobacco products including such treated tobacco materials are also provided.Type: ApplicationFiled: April 5, 2013Publication date: October 9, 2014Applicant: R.J. Reynolds Tobacco CompanyInventors: Serban C. Moldoveanu, Marvin Glenn Riddick, Jerry Wayne Marshall
-
Patent number: 8846642Abstract: A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligasaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosacchardide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life.Type: GrantFiled: April 10, 2013Date of Patent: September 30, 2014Assignee: Nestec S.A.Inventors: Marie-Claire Fichot, Norbert Sprenger, Francois-Pierre Martin, Sunil Kochhar, Serge Rezzi
-
Patent number: 8841427Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.Type: GrantFiled: February 15, 2013Date of Patent: September 23, 2014Assignee: Genzyme CorporationInventor: Yunxiang Zhu
-
Publication number: 20140271473Abstract: A metal ion nanocluster having a formula of X(OH)aYbZcMd(H2O)e. X, Y, Z, M, a, b, c, d, and e are defined herein. The nanocluster has a particle size of 2 to 500 nm and a molecular weight of 3500 to 1000000 Dalton. Also disclosed are a composition containing the nanocluster and a method of preparing the nanocluster.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: LG Bionano, LLCInventor: Chien-Chin Wu
-
Patent number: 8835403Abstract: The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of ?-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.Type: GrantFiled: February 25, 2005Date of Patent: September 16, 2014Inventors: Meiyu Geng, Huashi Guan, Xianliang Xin, Zhao Yang, Guangqiang Sun
-
Patent number: 8828967Abstract: New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight.Type: GrantFiled: June 8, 2011Date of Patent: September 9, 2014Assignee: Biofer S.p.A.Inventors: Michele Autuori, Dario Bosi, Alessandro Lapini Sacchetti, Egidio Marchi
-
Patent number: 8822549Abstract: An oxygen therapeutic composition, comprising a perfluorocarbon material, a viscosity modifier, a buffer, wherein the buffer stabilizes a pH of the composition at between about 6.5 to about 7.5, and wherein the composition comprises a viscosity of about 2.0 to about 3.5 mPas, and wherein the fluorocarbon has a boiling point of about 4 degrees Celsius to about 60 degrees Celsius.Type: GrantFiled: October 13, 2011Date of Patent: September 2, 2014Inventors: Jennifer L. Johnson, Evan C. Unger
-
Patent number: 8822432Abstract: A composition which can significantly accelerate equol production is provided. When formulated in a pharmaceutical preparation or a food or drink, this composition exerts effects of preventing a vascular disease by the cholesterol lowering function, preventing breast cancer or prostatic cancer, and preventing and/or treating osteoporosis. Also, when formulated in a feed or a pet food, the bone density is enhanced, so that it exerts effects to prevent weak legs of a pig, to strengthen egg shell of a laying hen, to prevent osteoporosis in a dog etc., and the like. It is a composition which comprises lactobionic acid, a salt of lactobionic acid or lactobionolactone as an active ingredient and a food or drink, a feed, a pet food or a pharmaceutical preparation, which contains the composition, and have effects to prevent and treat osteoporosis, an function to increase bone density, an effect to prevent breast cancer or prostatic cancer, and a cholesterol lowering function.Type: GrantFiled: June 15, 2007Date of Patent: September 2, 2014Assignee: Unitika Ltd.Inventors: Kenichi Oe, Takashi Kimura
-
Publication number: 20140243284Abstract: The present invention provides a compound of the formula (I) or (II), wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or aryl, and R9 is R9a, C(O)R9a or SO2R9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(?O), OR9b, OC(O)R9b, OSO2R9b, NHR9b, NHC(O)R9b and NHSO2R9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(?O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent.Type: ApplicationFiled: May 12, 2014Publication date: August 28, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Michael R. Boyd, Kirk R. Gustafson, Charles L. Cantrell
-
Patent number: 8815831Abstract: The invention provides a method to improve the efficacy of an antibiotic to inhibit the growth of Acinetobacter, said method comprising using said antibiotic together with an alginate oligomer. The Acinetobacter may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with Acinetobacter. In another aspect the method can be used to combat Acinetobacter contamination of a site e.g., for disinfection and cleaning purposes.Type: GrantFiled: June 3, 2010Date of Patent: August 26, 2014Assignee: Algipharma ASInventors: Edvar Onsoyen, Rolf Myrvold, Arne Dessen, David Thomas, Timothy Rutland Walsh